Additionally, in breast cancer cells, PRMT5 is phosphorylated at T139 and 144 by LKB1, and the mutation of these sites leads to a significant decrease in PRMT5 catalytic activity and reduces the interaction with its co-factors—MEP50, pICln, and RiOK1 [37]. The gene discussed is PRMT5; the disease is breast cancer.